Covalent and noncovalent targeting of the Tcf4/β-catenin strand interface with β-hairpin mimics
SL Blosser, N Sawyer, I Maksimovic, B Ghosh… - ACS chemical …, 2021 - ACS Publications
β-Strands are a fundamental component of protein structure, and these extended peptide
regions serve as binding epitopes for numerous protein–protein complexes. However …
regions serve as binding epitopes for numerous protein–protein complexes. However …
[HTML][HTML] 20 (S)-ginsenoside Rh2 inhibits the proliferation and induces the apoptosis of KG-1a cells through the Wnt/β-catenin signaling pathway
Y Chen, ZH Liu, J Xia, XP Li, KQ Li… - Oncology …, 2016 - spandidos-publications.com
Previous research has shown that total saponins of Panax ginseng (TSPG) and other
ginsenoside monomers inhibit the proliferation of leukemia cells. However, the effect has not …
ginsenoside monomers inhibit the proliferation of leukemia cells. However, the effect has not …
Enhancement of radiation sensitivity in lung cancer cells by a novel small molecule inhibitor that targets the β-catenin/Tcf4 interaction
Radiation therapy is an important treatment choice for unresectable advanced human lung
cancers, and a critical adjuvant treatment for surgery. However, radiation as a lung cancer …
cancers, and a critical adjuvant treatment for surgery. However, radiation as a lung cancer …
Modulation of complement activity
MD Hoarty, KA Dhamnaskar, D Elbaum… - US Patent …, 2018 - Google Patents
2017-01-09 Assigned to RA PHARMACEUTICALS, INC. reassignment RA
PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …
PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …
Modulation of complement activity
MD Hoarty, KA Dhamnaskar, D Elbaum… - US Patent …, 2019 - Google Patents
2019-01-02 Assigned to RA PHARMACEUTICALS, INC. reassignment RA
PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …
PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …
Modulation of complement activity
MD Hoarty, KA Dhamnaskar, D Elbaum… - US Patent …, 2019 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
54834568&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
54834568&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Modulators of complement activity
MD Hoarty, KA Dhamnaskar, D Elbaum… - US Patent …, 2019 - Google Patents
2018-03-27 Assigned to RA PHARMACEUTICALS, INC. reassignment RA
PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …
PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …
Modulators of complement activity
MD Hoarty, KA Dhamnaskar, D Elbaum… - US Patent …, 2020 - Google Patents
2019-05-23 Assigned to RA PHARMACEUTICALS, INC. reassignment RA
PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …
PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …
Modulators of complement activity
MD Hoarty, KA Dhamnaskar, D Elbaum… - US Patent …, 2018 - Google Patents
2017-08-23 Assigned to RA PHARMACEUTICALS, INC. reassignment RA
PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …
PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …
New homogeneous high-throughput assays for inhibitors of β-catenin/Tcf protein–protein interactions
The transcriptional activator β-catenin is the primary mediator of the canonical Wnt/β-catenin
signaling pathway. The aberrant formation of the β-catenin/T-cell factor (Tcf) complex leads …
signaling pathway. The aberrant formation of the β-catenin/T-cell factor (Tcf) complex leads …